Cost-effectiveness of human papillomavirus vaccine in China: a systematic review of modelling studies.

ABSTRACT:

Objectives

China suffers from high burdens of human papillomavirus (HPV) and cervical cancer, whereas the uptake of HPV vaccine remains low. The first Chinese domestic HPV vaccine was released in 2019. However, collective evidence on cost-effectiveness of HPV vaccination in China has yet to be established. We summarised evidence on the cost-effectiveness of HPV vaccine in China.

Design

Systematic review and narrative synthesis DATA SOURCES: PubMed, EMBASE, China National Knowledge Infrastructure and Wanfang Data were searched through 2 January 2021 ELIGIBILITY CRITERIA FOR SELECTING STUDIES: Cost-effectiveness studies using a modelling approach focusing on HPV vaccination interventions in the setting of China were included for review.

Data extraction and synthesis

We

SUBMITTER: Shi W 

PROVIDER: S-EPMC8655525 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature